The patent on hyperactivity-disorder drug Strattera is being challenged by Novartis AG’s Sandoz unit. Novartis is seeking a pre-emptive ruling that its proposed generic version of Strattera won’t infringe a Lilly patent that expires in 2017, or that the patent is invalid.
Icelandic drugmaker Actavis Group hf is already being sued by Lilly to block a generic version of Strattera, which generated $282.2 million in sales for the first half of the year for Lilly. In view of the Actavis suit, “Lilly has created an actual case or controversy against Sandoz with respect to infringement,” Sandoz said in its complaint.
For more information on this subject matter, please refer to the section on Drugs, Medical Devices, and Implants.